The expression level of PD-L1 within the tumor microenvironment, which is a target for PD-1/PD-L1 pathway blockade, has been extensively investigated as a predictive biomarker of the efficacy of anti-PD-1/PD-L1-based ICIs across various cancer types. The gene discussed is CD274; the disease is cancer.